| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:CAY10722
CAS:388086-13-3
Purity:98% Package:1G;10G;100G Remarks:Sirtuins (SIRTs) are a family of proteins that regulate cellular health. Sirtuins play a key role in regulating cellular homeostasis. SIRT1 Activator 3 is a member of the sirtuins (SIRTs), which is a
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:CAY10722;CAY10722,CAY-10722
CAS:388086-13-3
Purity:98% Package:50 mg
|
| Company Name: |
Suzhou Zhixin Biotechnology Co., Ltd.
|
| Tel: |
0512-65118909 15162312715 |
| Email: |
sales@szzxbio.com |
| Products Intro: |
Product Name:CAY10722
CAS:388086-13-3
Purity:98%+ Package:1g;10g;100g
|
|
| | CAY10722 Basic information |
| Product Name: | CAY10722 | | Synonyms: | CAY10722;N-[2-(2,4-Dichlorophenyl)-5-benzoxazolyl]benzeneacetamide;CAY10722,CAY-10722;Benzeneacetamide, N-[2-(2,4-dichlorophenyl)-5-benzoxazolyl]- | | CAS: | 388086-13-3 | | MF: | C21H14Cl2N2O2 | | MW: | 397.25 | | EINECS: | | | Product Categories: | | | Mol File: | 388086-13-3.mol |  |
| | CAY10722 Chemical Properties |
| Boiling point | 598.7±50.0 °C(Predicted) | | density | 1.406±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml; Ethanol: Slightly soluble | | form | A crystalline solid | | pka | 13.04±0.43(Predicted) |
| | CAY10722 Usage And Synthesis |
| Description | CAY10722 is an inhibitor of sirtuin 3 (SIRT3), a class III HDAC (71% inhibition at 200 μM).1 SIRT3 is involved in modulating metabolic homeostasis as a NAD+-dependent protein deacetylase in the mitochondria. SIRT3 functions as either an oncogene or tumor suppressor, depending on cancer cell type.2,3 High SIRT3 expression in patient-derived esophageal cancer tissues is associated with shorter survival and, in mice, downregulation leads to a lower tumor load.4 In contrast, low SIRT3 expression in patient-derived breast cancer cells is correlated with shorter survival.5 | | References | 1. Salo, H.S., Latinen, T., Poso, A., et al. Identification of novel SIRT3 inhibitor scaffolds by virtual screening Bioorg. Med. Chem. Lett. 23(10),2990-2995(2013).
2. Chen, Y., Fu, L., Wen, X., et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer Cell Death Dis. 5(e1047),1-7(2014).
3. Xiong, Y., Wang, M., Zhao, J., et al. Sirtuin 3: A Janus face in cancer (Review) Int. J. Oncol. 49(6),2227-2235(2016).
4. Zhao, Y., Yang, H., Wang, X., et al. Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer Ann. Diagn. Pathol. 17(6),483-485(2013).
5. Desouki, M.M., Doubinskaia, I., Gius, D., et al. Decreased mitochondrial SIRT3 expression is potential molecular biomarker associated with poor outcome in breast cancer Hum. Pathol. 45(5),1071–1077(2014). |
| | CAY10722 Preparation Products And Raw materials |
|